Neutral HMO Nutritional Composition for Inflammation Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective solutions for modulating inflammation in adults and elderly individuals, particularly in reducing platelet neutrophil complex (PNC) formation, which is associated with various inflammatory diseases, and there are no vaccines available for minimizing inflammatory diseases.
Innovation Solution
A nutritional composition containing neutral human milk oligosaccharides (HMOs) such as 2′-fucosyllactose (2′FL) and lacto-N-neotetraose (LNnT), alone or in combination with 3-fucosyllactose (3FL), which are formulated in concentrations ranging from 0.001 mg/mL to 25 mg/mL, to reduce inflammation and PNC formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neutral human milk oligosaccharides are used to reduce inflammation and PNC formation, then immune modulation and anti-inflammatory effects are improved, but the complexity of nutritional composition formulation increases
Solution Approach 1:
The patent applies parameter changes by optimizing the concentration ranges of specific HMOs (2′FL at 0.001-25 mg/mL, LNnT at 0.001-25 mg/mL, 3FL at 0.001-10 mg/mL) to achieve effective anti-inflammatory effects while maintaining formulation feasibility. This systematic parameter optimization resolves the contradiction between efficacy and formulation complexity.
Solution Approach 2:
The patent uses composite materials by combining multiple neutral HMOs (2′-fucosyllactose, lacto-N-neotetraose, and 3-fucosyllactose) in specific concentrations to create a synergistic nutritional composition. This composite approach enhances the anti-inflammatory effect while distributing the complexity across multiple well-defined components.
2Reliability
If specific concentrations of HMOs are used to achieve effective inflammation reduction, then therapeutic efficacy is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent establishes broad yet effective concentration ranges for each HMO component (2′FL: 0.001-25 mg/mL, LNnT: 0.001-25 mg/mL, 3FL: 0.001-10 mg/mL), which provides manufacturing flexibility while ensuring therapeutic efficacy. This parameter specification balances precision requirements with practical manufacturability.
3Object-affected harmful factors
If neutral HMOs are used to modulate immune response and reduce cytokine production, then safety is improved, but the mechanism complexity increases
Solution Approach 1:
The patent extracts and isolates specific neutral HMOs (2′-fucosyllactose, lacto-N-neotetraose, 3-fucosyllactose) from the complex mixture of all human milk oligosaccharides. This extraction approach identifies the key active components responsible for immune modulation while simplifying the overall mechanism understanding and formulation.
Data Source
AI summary
Disclosed is a nutritional composition for use in modulating or reducing inflammation in an adult or elderly individual in need thereof. In some aspects, the nutritional composition comprises a neutral human milk oligosaccharide.